EP0872552A1
(en)
*
|
1997-04-15 |
1998-10-21 |
Leadd B.V. |
A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
|
NL9101680A
(nl)
|
1991-10-04 |
1993-05-03 |
Tno |
Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
|
FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
US6080569A
(en)
*
|
1993-06-24 |
2000-06-27 |
Merck & Co., Inc. |
Adenovirus vectors generated from helper viruses and helper-dependent vectors
|
DE69533295T3
(de)
*
|
1994-02-16 |
2009-07-16 |
The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services |
Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
|
US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
DE69531387T2
(de)
|
1994-08-16 |
2004-04-22 |
Crucell Holland B.V. |
Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
|
US5998205A
(en)
*
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US6281010B1
(en)
*
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US6783980B2
(en)
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6265212B1
(en)
*
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
KR100449181B1
(ko)
|
1995-06-15 |
2005-01-24 |
크루셀 홀란드 비.브이. |
유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
JPH11510050A
(ja)
|
1995-07-25 |
1999-09-07 |
イントロヘーネ ベスローテン フェンノートシャップ |
標的遺伝子送達のための方法および手段
|
EP0870044B1
(en)
*
|
1995-12-01 |
2004-04-14 |
Crucell Holland B.V. |
Regulated protein expression in stably transfected mammalian cells
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
AU5253998A
(en)
*
|
1996-11-13 |
1998-06-03 |
Board Of Regents, The University Of Texas System |
Diminishing viral gene expression by promoter replacement
|
DE69727492T2
(de)
|
1996-12-05 |
2004-12-16 |
Crucell Holland B.V. |
Genetische modifikation der hämatopoietischen repopulation von stammzellen in primaten
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
EP0973866A4
(en)
|
1997-03-04 |
2000-04-19 |
Baxter Int |
ADENOVIRUS E1-COMPLEMENTING CELL LINES
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
FR2774699B1
(fr)
|
1997-11-17 |
2003-10-03 |
Rhone Poulenc Rorer Sa |
Methode de reduction des evenements de recombinaison homologue
|
WO1999027123A2
(en)
*
|
1997-11-26 |
1999-06-03 |
Board Of Regents, The University Of Texas System |
Modified sv40 viral vectors
|
NZ505325A
(en)
|
1997-12-23 |
2003-07-25 |
Crucell Holland B |
Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
|
CA2319112C
(en)
|
1998-02-13 |
2003-10-28 |
Genetrace Systems, Inc. |
Use of ribozymes for functionating genes
|
US5981225A
(en)
*
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6670188B1
(en)
*
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP0959136A1
(en)
|
1998-05-20 |
1999-11-24 |
Introgene B.V. |
Targeted delivery through a cationic amino acid transporter
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US6900049B2
(en)
*
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
EP1124976A1
(en)
*
|
1998-10-27 |
2001-08-22 |
Crucell Holland B.V. |
Improved aav vector production
|
IT1302403B1
(it)
*
|
1998-11-06 |
2000-09-05 |
Angeletti P Ist Richerche Bio |
Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
|
IL133032A
(en)
*
|
1998-11-20 |
2007-06-03 |
Introgene Bv |
Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
EP1016726A1
(en)
*
|
1998-12-30 |
2000-07-05 |
Introgene B.V. |
Gene therapy to promote angiogenesis
|
US6869936B1
(en)
|
1999-03-04 |
2005-03-22 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
ATE403006T1
(de)
*
|
1999-03-04 |
2008-08-15 |
Crucell Holland Bv |
Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
|
US20060099685A1
(en)
*
|
1999-04-15 |
2006-05-11 |
Yallop Christopher A |
Recombinant expression of factor VIII in human cells
|
JP4210036B2
(ja)
†
|
1999-04-15 |
2009-01-14 |
クルセル ホランド ベー ヴェー |
ヒト細胞における組み換え蛋白質の生産
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
US20050170463A1
(en)
*
|
1999-04-15 |
2005-08-04 |
Abraham Bout |
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
WO2001007571A1
(en)
*
|
1999-04-23 |
2001-02-01 |
Introgene B.V. |
Means and methods for nucleic acid transfer
|
KR100741247B1
(ko)
|
1999-05-17 |
2007-07-19 |
크루셀 홀란드 비.브이. |
아데노바이러스 타입 35의 적어도 하나의 구성성분을포함하는 아데노바이러스 유래 유전자 전달체
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
EP1200622A4
(en)
*
|
1999-07-06 |
2004-12-22 |
Merck & Co Inc |
HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS
|
EP1067190A1
(en)
*
|
1999-07-09 |
2001-01-10 |
Introgene B.V. |
Gene therapy for enhancing and/or inducing angiogenesis
|
CA2384439A1
(en)
*
|
1999-09-10 |
2001-03-22 |
Crucell Holland B.V. |
Modified adenoviral vectors for use in gene therapy
|
EP1083229A1
(en)
*
|
1999-09-10 |
2001-03-14 |
Introgene B.V. |
Modified adenoviral vectors for use in gene therapy
|
EP1083228A1
(en)
*
|
1999-09-10 |
2001-03-14 |
Introgene B.V. |
Modified adenoviral vectors for use in gene therapy
|
US6365394B1
(en)
|
1999-09-29 |
2002-04-02 |
The Trustees Of The University Of Pennsylvania |
Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
|
US7115391B1
(en)
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
DE19955558C2
(de)
*
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
US7527961B2
(en)
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
US7521220B2
(en)
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
JP2003516743A
(ja)
*
|
1999-12-14 |
2003-05-20 |
ジェノボ, インコーポレイテッド |
複製不能アデノウイルスの製造のための方法および組成物
|
EP1248653A2
(en)
*
|
2000-01-07 |
2002-10-16 |
Stichting Klinische Farmacologie Groningen |
Gene therapy to promote angiogenesis and/or the treatment of heart failure
|
US7132277B1
(en)
|
2000-01-31 |
2006-11-07 |
Merck & Co., Inc. |
Helper dependent vector system for gene therapy
|
ATE419338T1
(de)
*
|
2000-03-24 |
2009-01-15 |
Cell Genesys Inc |
Menschliche zellspezifische urotheliale regulatorische sequenzen der transkription des uroplakins, dessen vektoren und verwendungsverfahren
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
KR20010064682A
(ko)
*
|
2000-07-01 |
2001-07-11 |
김재호 |
E1b가 감쇠된 아데노바이러스를 이용한 cd/5-fc및 hsv-1 tk/gcv의 이중 자멸 유전자 시스템
|
US20020164333A1
(en)
*
|
2000-07-10 |
2002-11-07 |
The Scripps Research Institute |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
US7223406B2
(en)
*
|
2000-07-21 |
2007-05-29 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
US6852323B2
(en)
*
|
2000-07-21 |
2005-02-08 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6733993B2
(en)
*
|
2000-09-15 |
2004-05-11 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
|
US20040101957A1
(en)
*
|
2001-09-14 |
2004-05-27 |
Emini Emilio A. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
|
CA2421864A1
(en)
*
|
2000-09-20 |
2002-03-28 |
Crucell Holland B.V. |
Transduction of dendritic cells using adenoviral vectors
|
DE60138403D1
(de)
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
US6573092B1
(en)
*
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
IL152423A0
(en)
*
|
2001-02-23 |
2003-05-29 |
Novartis Ag |
Novel vector constructs
|
JP2004533815A
(ja)
|
2001-03-14 |
2004-11-11 |
ミリアド・ジェネティックス・インコーポレイテッド |
Tsg101−gag相互作用およびその使用
|
EP1256803A1
(en)
*
|
2001-05-07 |
2002-11-13 |
Crucell Holland B.V. |
Methods for the identification of antiviral compounds
|
US6682929B2
(en)
|
2001-07-23 |
2004-01-27 |
Genvec, Inc. |
Adenovector complementing cells
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
US20030119771A1
(en)
*
|
2001-08-22 |
2003-06-26 |
Rompaey Luc Van |
Modulators of bone homeostasis identified in a high-throughput screen
|
CA2461380C
(en)
|
2001-10-11 |
2011-03-22 |
Merck & Co., Inc. |
Hepatitis c virus vaccine
|
ES2344253T3
(es)
|
2001-10-11 |
2010-08-23 |
MERCK SHARP & DOHME CORP. |
Vacuna contra el virus de la hepatitis c.
|
EA012340B1
(ru)
|
2001-10-29 |
2009-10-30 |
Круселл Холланд Б.В. |
Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac
|
NZ533124A
(en)
*
|
2001-12-07 |
2005-11-25 |
Crucell Holland B |
Production of viruses, viral isolates and vaccines
|
AU2002353662B2
(en)
*
|
2001-12-17 |
2009-04-23 |
Crucell Holland B.V. |
Production of F(ab')2 fragments in mammalian cells
|
EP1466016A2
(en)
|
2002-01-09 |
2004-10-13 |
Riken Institute Of Physical And Chemical Research |
Cancer profiles
|
JP4488290B2
(ja)
*
|
2002-01-24 |
2010-06-23 |
ザ・スクリップス・リサーチ・インスティテュート |
効率的ターゲティングのためのファイバーシャフト変異
|
EP1474533B1
(en)
*
|
2002-02-20 |
2006-04-26 |
Merck & Co., Inc. |
Method of determining adenovirus particle concentration
|
DK3483183T3
(da)
|
2002-03-01 |
2021-06-21 |
Immunomedics Inc |
Immunokonjugat omfattende humaniserede rs7-antistoffer
|
US7344873B2
(en)
*
|
2002-03-29 |
2008-03-18 |
Merck & Co., Inc. |
Methods of adenovirus production
|
US7582290B2
(en)
*
|
2002-04-08 |
2009-09-01 |
The Johns Hopkins University |
Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
|
PL208588B1
(pl)
*
|
2002-04-25 |
2011-05-31 |
Crucell Holland Bv |
Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa
|
DK1497438T3
(da)
*
|
2002-04-25 |
2010-01-04 |
Crucell Holland Bv |
Midler og fremgangsmåder til fremstilling af adenovirusvektorer
|
US20030219696A1
(en)
*
|
2002-05-23 |
2003-11-27 |
Moreland Gerald W. |
Method and apparatus for preventing backflow in dental saliva evacuators
|
EP2301968A3
(en)
|
2002-06-14 |
2011-06-29 |
Immunomedics, Inc. |
Humanized monoclonal antibody HPAM4
|
US7226755B1
(en)
*
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
US7507568B2
(en)
*
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
US20080153083A1
(en)
*
|
2003-10-23 |
2008-06-26 |
Crucell Holland B.V. |
Settings for recombinant adenoviral-based vaccines
|
EP1553983A2
(en)
*
|
2002-10-23 |
2005-07-20 |
Crucell Holland B.V. |
New settings for recombinant adenoviral-based vaccines
|
US20050221493A1
(en)
*
|
2002-12-04 |
2005-10-06 |
Crucell Holland B.V. |
Recombinant virus production for the manufacturing of vaccines
|
EP1573012B1
(en)
|
2002-12-17 |
2011-11-30 |
Crucell Holland B.V. |
Recombinant viral-based malaria vaccines
|
WO2004056986A2
(en)
*
|
2002-12-20 |
2004-07-08 |
Chromagenics B.V. |
Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
|
WO2004060346A2
(en)
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
US20040166091A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
WO2004092397A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Novartis Ag |
Tmprss2 regulatory sequences and uses thereof
|
US20070212675A1
(en)
*
|
2003-04-15 |
2007-09-13 |
Novartis Ag |
Flap Endonuclease (Fen1) Regulatory Sequences And Uses Thereof
|
NZ542585A
(en)
|
2003-05-09 |
2007-11-30 |
Crucell Holland Bv |
Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
|
DK1626992T3
(da)
*
|
2003-05-23 |
2010-09-20 |
Crucell Holland Bv |
Produktion af rekombinant IgM i PER.C6-celler
|
CA2526120A1
(en)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
US20060019256A1
(en)
*
|
2003-06-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
US7026164B2
(en)
*
|
2003-07-03 |
2006-04-11 |
Cell Genesys, Inc. |
Adenovirus packaging cell lines
|
US20050186178A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Ennist David L. |
Oncolytic adenoviral vectors encoding GM-CSF
|
WO2005033320A1
(en)
*
|
2003-10-02 |
2005-04-14 |
Crucell Holland B.V. |
Packaging cells for recombinant adenovirus
|
US7482156B2
(en)
*
|
2003-10-15 |
2009-01-27 |
Cell Genesys, Inc. |
Hepatocellular carcinoma specific promoter and uses thereof
|
EP1528101A1
(en)
*
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
JP2007511507A
(ja)
|
2003-11-14 |
2007-05-10 |
ジェンベク、インコーポレイティッド |
癌を処置するための治療レジメン
|
PL2163260T3
(pl)
|
2004-01-23 |
2017-12-29 |
Msd Italia S.R.L. |
Szympansie adenowirusowe nośniki szczepionek
|
CA2554779A1
(en)
*
|
2004-02-03 |
2005-08-18 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
JP2007522814A
(ja)
*
|
2004-02-23 |
2007-08-16 |
クルセル ホランド ベー ヴェー |
ウイルスの精製方法
|
US7473418B2
(en)
*
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
AU2005243730B2
(en)
|
2004-04-12 |
2010-05-27 |
Genvec, Inc. |
Method of using adenoviral vectors to induce an immune response
|
JP2008505853A
(ja)
|
2004-04-13 |
2008-02-28 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
|
AU2005287383B2
(en)
*
|
2004-05-25 |
2011-09-22 |
Chimeros, Inc. |
Self-assembling nanoparticle drug delivery system
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
US20060062764A1
(en)
*
|
2004-08-25 |
2006-03-23 |
Seshidar-Reddy Police |
Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
|
EP1784493A2
(en)
*
|
2004-09-01 |
2007-05-16 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
PL2229956T3
(pl)
|
2004-09-13 |
2013-09-30 |
Genzyme Corp |
Konstrukty multimeryczne
|
CN102626336A
(zh)
|
2004-10-05 |
2012-08-08 |
建新公司 |
台阶式插管
|
AU2005294265A1
(en)
|
2004-10-06 |
2006-04-20 |
University Of Rochester |
Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
|
CN101203530A
(zh)
|
2004-10-28 |
2008-06-18 |
匹兹堡大学高等教育联邦体系 |
关于脊髓损伤疼痛的外周递送的谷氨酸脱羧酶基因治疗
|
US8999667B2
(en)
*
|
2004-11-08 |
2015-04-07 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
AU2005300503B2
(en)
*
|
2004-11-08 |
2010-12-16 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
US8039230B2
(en)
*
|
2004-11-08 |
2011-10-18 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
DK1809750T3
(da)
*
|
2004-11-08 |
2012-06-25 |
Chromagenics Bv |
Selektion af værtsceller, der udtrykker protein ved høje niveauer
|
US20060195935A1
(en)
*
|
2004-11-08 |
2006-08-31 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
ATE516343T1
(de)
*
|
2004-12-13 |
2011-07-15 |
Canji Inc |
Zellinien zur produktion von replikationsdefektem adenovirus
|
EP2110667A1
(en)
|
2005-01-20 |
2009-10-21 |
University Of Rochester |
Thoredoxin interacting protein (TXNIP) as regulator of vascular function
|
JP2008538894A
(ja)
*
|
2005-02-11 |
2008-11-13 |
メルク エンド カムパニー インコーポレーテッド |
アデノウイルス血清型26ベクター、核酸およびそれにより製造されたウイルス
|
ES2317517T5
(es)
*
|
2005-04-11 |
2016-01-21 |
Crucell Holland B.V. |
Purificación de virus usando ultrafiltración
|
US20060234347A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Harding Thomas C |
Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
|
WO2006130581A2
(en)
|
2005-05-31 |
2006-12-07 |
Avigen, Inc. |
Methods for delivering genes
|
WO2006138275A2
(en)
*
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
WO2006135886A2
(en)
*
|
2005-06-13 |
2006-12-21 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
WO2006133911A2
(en)
*
|
2005-06-17 |
2006-12-21 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Hepatitis c virus nucleic acid vaccine
|
JP5137829B2
(ja)
*
|
2005-07-22 |
2013-02-06 |
クルセル ホランド ベー ヴェー |
コロナウイルス類生産用の細胞系
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
BRPI0615400A2
(pt)
*
|
2005-08-31 |
2011-05-17 |
Genvec Inc |
vacinas para malária baseadas em vetor adenoviral
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
JP5512125B2
(ja)
|
2005-09-12 |
2014-06-04 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
前立腺癌における再発性遺伝子融合
|
US8652467B2
(en)
*
|
2005-10-14 |
2014-02-18 |
The Regents Of The University Of Michigan |
Dek protein compositions and methods of using the same
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
DK2500360T3
(da)
|
2005-10-31 |
2015-10-26 |
Oncomed Pharm Inc |
Sammensætninger og fremgangsmåder til diagnosticering og behandling af cancer
|
EP1945754B1
(en)
*
|
2005-10-31 |
2014-07-23 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
EP1951297A2
(en)
|
2005-11-10 |
2008-08-06 |
GenVec, Inc. |
Adenoviral vector-based foot-and-mouth disease vaccine
|
JP5097714B2
(ja)
*
|
2005-12-12 |
2012-12-12 |
カンジ,インコーポレイテッド |
E1領域内の発現カセットと不活性化されたe2bポリメラーゼを有するアデノウイルス発現ベクター
|
AR059089A1
(es)
|
2006-01-20 |
2008-03-12 |
Genzyme Corp |
Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
|
HUE040490T2
(hu)
|
2006-02-09 |
2019-03-28 |
Genzyme Corp |
Lassú intraventrikuláris szállítás
|
US20080019961A1
(en)
*
|
2006-02-21 |
2008-01-24 |
Regents Of The University Of Michigan |
Hedgehog signaling pathway antagonist cancer treatment
|
US7968700B2
(en)
*
|
2006-03-20 |
2011-06-28 |
Chromagenics B.V. |
Expression augmenting DNA fragments, use thereof, and methods for finding thereof
|
EP2004697A2
(en)
*
|
2006-04-07 |
2008-12-24 |
The Procter & Gamble Company |
Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
|
JP2009533350A
(ja)
*
|
2006-04-07 |
2009-09-17 |
キメロス, インコーポレイテッド |
B細胞悪性疾患を処置するための組成物および方法
|
WO2007149594A2
(en)
*
|
2006-06-23 |
2007-12-27 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
US20100159450A1
(en)
|
2006-06-23 |
2010-06-24 |
Susanne Wagner |
Dpyd gene variants and use thereof
|
US7795444B2
(en)
*
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
HUE028365T2
(en)
|
2006-07-14 |
2016-12-28 |
Dpx Holdings Bv |
An improved method for cell culture
|
US8298801B2
(en)
|
2006-07-17 |
2012-10-30 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
US20080261216A1
(en)
*
|
2006-09-08 |
2008-10-23 |
The Regents Of The University Of Michigan |
HERV Group II Viruses In Lymphoma And Cancer
|
EP2114445A2
(en)
*
|
2007-01-09 |
2009-11-11 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US11371194B2
(en)
*
|
2007-01-19 |
2022-06-28 |
Brock Usa, Llc |
Base for turf system
|
EP2106439B1
(en)
|
2007-01-24 |
2014-11-12 |
The Regents of the University of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
DE602008004476D1
(de)
*
|
2007-03-09 |
2011-02-24 |
Vectorlogics Inc |
Zellen für adenovirusvektor- und proteinherstellung
|
US20090226525A1
(en)
*
|
2007-04-09 |
2009-09-10 |
Chimeros Inc. |
Self-assembling nanoparticle drug delivery system
|
US20090324596A1
(en)
*
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
AU2008275304B2
(en)
|
2007-07-06 |
2012-07-26 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
EP2597464B1
(en)
|
2007-08-16 |
2015-02-25 |
The Regents of the University of Michigan |
Metabolomic profiling of prostate cancer
|
DE102007041655A1
(de)
|
2007-09-03 |
2009-03-05 |
Medicyte Gmbh |
Vermehrung von primären Zellen und deren Verwendung
|
WO2009048909A1
(en)
*
|
2007-10-08 |
2009-04-16 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
TWI488640B
(zh)
|
2008-04-16 |
2015-06-21 |
Ferring Int Ct Sa |
藥學製劑
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
US8193151B2
(en)
*
|
2008-04-25 |
2012-06-05 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias
|
JP5684122B2
(ja)
*
|
2008-07-15 |
2015-03-11 |
クルセル ホランド ベー ヴェー |
Per.c6細胞の培養およびそれからの生成物の生産のための拡張可能なプロセス
|
US8871515B2
(en)
*
|
2008-09-17 |
2014-10-28 |
Isogenis, Inc. |
Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
|
CN105079805A
(zh)
|
2008-09-26 |
2015-11-25 |
昂考梅德药品有限公司 |
卷曲蛋白结合药剂及其应用
|
JP2012504423A
(ja)
|
2008-10-01 |
2012-02-23 |
クインテッセンス バイオサイエンシズ,インコーポレーテッド |
治療用リボヌクレアーゼ
|
US20110184154A1
(en)
*
|
2008-10-17 |
2011-07-28 |
Percivia Llc |
Cell broth clarification and host cell protein removal
|
MX2011004292A
(es)
*
|
2008-11-03 |
2011-05-31 |
Crucell Holland Bv |
Metodo para la produccion de vectores adenovirales.
|
CA2749113A1
(en)
|
2009-01-09 |
2010-07-15 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in cancer
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
AU2010206195B2
(en)
|
2009-01-20 |
2016-03-10 |
Transgene Sa |
Soluble ICAM-1 as biomarker for prediction of therapeutic response
|
US8772238B2
(en)
|
2009-03-18 |
2014-07-08 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
|
RU2542435C2
(ru)
|
2009-03-24 |
2015-02-20 |
Трансжене Са |
Биомаркер для мониторинга пациентов
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
SI2419728T1
(sl)
|
2009-04-17 |
2014-03-31 |
Transgene Sa |
Bio-označevalec za monitoring pacientov
|
US8357661B2
(en)
|
2009-04-23 |
2013-01-22 |
Crucell Holland B.V. |
Recombinant human Alpha1-antitrypsin
|
CA2765099A1
(en)
|
2009-06-10 |
2010-12-16 |
New York University |
Phosphorylated tau peptide for use in the treatment of tauopathy
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
KR101426125B1
(ko)
|
2009-07-06 |
2014-08-06 |
에르피오 세러퓨틱스 인코포레이티드 |
암 세포의 전이 예방을 위한 화합물, 조성물 및 방법
|
WO2011003615A2
(en)
|
2009-07-08 |
2011-01-13 |
Glycotope Gmbh |
Perfusion bioreactor
|
SG176619A1
(en)
|
2009-07-10 |
2012-01-30 |
Transgene Sa |
Biomarker for selecting patients and related methods
|
MA33429B1
(fr)
*
|
2009-07-16 |
2012-07-03 |
Crucell Holland Bv |
Production de poliovirus à titres élevés pour la production de vaccins
|
CA2770075C
(en)
|
2009-08-07 |
2021-08-24 |
Perrine Martin |
Composition for treating hbv infection
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
AU2010305768B2
(en)
*
|
2009-10-15 |
2015-05-14 |
Crucell Holland B.V. |
Process for adenovirus purification from high cell density cultures
|
PL2488636T3
(pl)
*
|
2009-10-15 |
2014-07-31 |
Crucell Holland Bv |
Sposób oczyszczania cząsteczek adenowirusów z hodowli o wysokim zagęszczeniu komórkowym
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
BR112012010824A2
(pt)
|
2009-11-09 |
2018-03-06 |
Genvec Inc |
adenovirus simios e métodos de uso
|
CA2785594C
(en)
|
2010-01-08 |
2018-04-17 |
Profibrix Bv |
Fibrinogen preparations enriched in fibrinogen with an extended alpha chain
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
ES2578514T3
(es)
|
2010-02-15 |
2016-07-27 |
Crucell Holland B.V. |
Método para la producción de vectores adenovíricos
|
US20110237461A1
(en)
|
2010-03-17 |
2011-09-29 |
The Regents Of The University Of Michigan |
Using phage epitopes to profile the immune response
|
CN102892429B
(zh)
|
2010-03-17 |
2016-08-31 |
康奈尔大学 |
基于被破坏的腺病毒的抗滥用药物疫苗
|
JP2013527753A
(ja)
|
2010-03-23 |
2013-07-04 |
イントレキソン コーポレーション |
治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
|
KR20130043102A
(ko)
|
2010-04-01 |
2013-04-29 |
온코메드 파마슈티칼스, 인크. |
프리즐드-결합 작용제 및 그의 용도
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
US8771709B2
(en)
|
2010-09-20 |
2014-07-08 |
Crucell Holland B.V. |
Therapeutic vaccination against active Tuberculosis
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
DE102010041958A1
(de)
|
2010-10-04 |
2012-04-05 |
Medicyte Gmbh |
Geeignete Hepatozyten für in-vitro Genotoxitätstests
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
EP2658567A4
(en)
|
2010-12-28 |
2014-09-24 |
Univ Rochester |
METHOD FOR MODIFYING INSULIN SIGNAL TRANSMISSION BY BILIVERDINREDUCTASE (BVR) AND BVR-DERIVED PEPTIDES
|
WO2012106281A2
(en)
|
2011-01-31 |
2012-08-09 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
CN103534355A
(zh)
|
2011-03-04 |
2014-01-22 |
英特瑞克斯顿股份有限公司 |
条件性表达蛋白质的载体
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
EA029234B1
(ru)
|
2011-07-06 |
2018-02-28 |
Сюкехусет Сёрланнет Хф |
Нацеленная на egfr терапия
|
TWI575070B
(zh)
|
2011-07-12 |
2017-03-21 |
傳斯堅公司 |
Hbv聚合酶突變體
|
PL2753346T3
(pl)
|
2011-09-07 |
2020-10-19 |
Mount Sinai School Of Medicine |
Ceramidaza i różnicowanie komórek
|
JP2014527072A
(ja)
|
2011-09-09 |
2014-10-09 |
バイオメド リアルティー, エル.ピー. |
ウイルスタンパク質の集合を制御するための方法および組成物
|
WO2013045668A2
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
JP6757119B2
(ja)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
アーフェンアデノウイルス(ゴリラ)又はアデノウイルスベクター、及び使用方法
|
EP2764013B1
(en)
|
2011-10-05 |
2022-01-26 |
GenVec, Inc. |
Adenoviral vectors and methods of use
|
EP2764014B1
(en)
|
2011-10-05 |
2022-02-09 |
GenVec, Inc. |
Adenoviral vectors and methods of use
|
EP2764011B1
(en)
|
2011-10-05 |
2021-04-07 |
GenVec, Inc. |
Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
KR101427200B1
(ko)
|
2011-11-24 |
2014-08-07 |
주식회사 바이로메드 |
아데노바이러스 생산 신규 세포주 및 그의 용도
|
US20150004144A1
(en)
|
2011-12-02 |
2015-01-01 |
The General Hospital Corporation |
Differentiation into brown adipocytes
|
WO2013085624A1
(en)
|
2011-12-08 |
2013-06-13 |
Virovek, Inc. |
Vectors harboring toxic genes, methods and uses therefor
|
WO2013116591A1
(en)
|
2012-02-02 |
2013-08-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccine
|
CA2863964C
(en)
|
2012-02-07 |
2021-10-26 |
Global Bio Therapeutics Usa, Inc. |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
NZ628385A
(en)
|
2012-03-12 |
2016-09-30 |
Crucell Holland Bv |
Batches of recombinant adenovirus with altered terminal ends
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
NZ630649A
(en)
|
2012-03-22 |
2016-12-23 |
Janssen Vaccines & Prevention Bv |
Vaccine against rsv
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
EP2855669B1
(en)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modified serotype 28 adenoviral vectors
|
EP2855511B1
(en)
|
2012-05-29 |
2019-07-24 |
GenVec, Inc. |
Herpes simplex virus vaccine
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
EA029492B1
(ru)
|
2012-07-10 |
2018-04-30 |
Трансген Са |
Вакцина на основе микобактериальных антигенов
|
MX360120B
(es)
|
2012-08-03 |
2018-10-23 |
Sanofi Pasteur |
Produccion de virus infecciosos de influenza.
|
US9605074B2
(en)
|
2012-08-30 |
2017-03-28 |
The General Hospital Corporation |
Multifunctional nanobodies for treating cancer
|
EP2908853B1
(en)
|
2012-10-21 |
2018-12-05 |
University Of Rochester |
Thy1 (cd90) as a therapy to control adipose tissue accumulation
|
EP2911691B1
(en)
|
2012-10-23 |
2018-10-10 |
OncoMed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
WO2014078688A2
(en)
|
2012-11-16 |
2014-05-22 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and use thereof
|
WO2014095088A1
(en)
|
2012-12-21 |
2014-06-26 |
Sykehuset Sørlandet Hf |
Egfr targeted therapy of neurological disorders and pain
|
EP2950885B1
(en)
|
2013-02-04 |
2018-11-21 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a wnt pathway inhibitor
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
KR101606910B1
(ko)
|
2013-03-29 |
2016-04-04 |
충북보건과학대학교 산학협력단 |
아데노바이러스 벡터 생산용 a549 기반 세포주
|
SG10201912901YA
(en)
|
2013-04-17 |
2020-02-27 |
Genzyme Corp |
Compositions and methods for treating and preventing macular degeneration
|
US9822418B2
(en)
|
2013-04-22 |
2017-11-21 |
Icahn School Of Medicine At Mount Sinai |
Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
|
EP2988780B1
(en)
|
2013-04-25 |
2018-12-26 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble prefusion rsv f polypeptides
|
JP6649250B2
(ja)
|
2013-05-21 |
2020-02-19 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
操作されたヘム結合性構成物およびその使用
|
CN105408348B
(zh)
|
2013-06-17 |
2021-07-06 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
ES2525768B1
(es)
*
|
2013-06-24 |
2015-10-07 |
Curaxis, S.L. |
Procedimiento para la producción de proteínas recombinantes glicosiladas.
|
WO2015021443A1
(en)
|
2013-08-08 |
2015-02-12 |
Global Bio Therapeutics Usa, Inc. |
Clamp device for minimally invasive procedures and uses thereof
|
HUE041791T2
(hu)
|
2013-09-19 |
2019-05-28 |
Janssen Vaccines & Prevention Bv |
Javított adenovírus-készítmények
|
US10421986B2
(en)
|
2013-09-30 |
2019-09-24 |
Janssen Vaccines & Prevention B.V. |
Method for the clarification of high-density crude cell culture harvest
|
EP3092000A1
(en)
|
2014-01-09 |
2016-11-16 |
Transgene SA |
Fusion of heterooligomeric mycobacterial antigens
|
MX2016010215A
(es)
|
2014-02-06 |
2016-11-15 |
Genzyme Corp |
Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
|
EP2927685A1
(en)
|
2014-04-02 |
2015-10-07 |
Medicyte GmbH |
Suitable hepatocytes for in-vitro hepatitis tests
|
KR102364111B1
(ko)
|
2014-07-24 |
2022-02-17 |
얀센 백신스 앤드 프리벤션 비.브이. |
세포 배양물로부터 폴리오바이러스의 정제 방법
|
MX2017002933A
(es)
|
2014-09-07 |
2017-05-30 |
Selecta Biosciences Inc |
Metodos y composiciones para atenuar las respuestas inmunes del vector de transferencia anti-viral de edicion del gen.
|
JP7095990B2
(ja)
|
2014-09-18 |
2022-07-05 |
シーダーズ-サイナイ メディカル センター |
線維症を治療するための組成物及び方法
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
NZ730802A
(en)
|
2014-11-04 |
2021-12-24 |
Janssen Vaccines & Prevention Bv |
Therapeutic hpv16 vaccines
|
EP3259374B1
(en)
|
2015-02-19 |
2019-08-21 |
Janssen Vaccines & Prevention B.V. |
Method for quantification of virus particles using capillary zone electrophoresis.
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
US20180052173A1
(en)
|
2015-03-18 |
2018-02-22 |
Janssen Vaccines & Prevention B.V. |
Assays for recombinant expression systems
|
EP3283634B1
(en)
|
2015-04-14 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
US20180112006A1
(en)
|
2015-04-17 |
2018-04-26 |
The General Hospital Corporation |
Agents, systems and methods for treating cancer
|
CN107708718B
(zh)
|
2015-04-22 |
2022-01-11 |
西达-赛奈医疗中心 |
用于治疗2型糖尿病的肠内递送的苦味寡肽
|
KR20180026734A
(ko)
|
2015-07-07 |
2018-03-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 가용성 융합-전 rsv f 폴리펩티드
|
PL3319633T3
(pl)
|
2015-07-07 |
2021-04-19 |
Janssen Vaccines & Prevention B.V. |
Szczepionka przeciwko rsv
|
SG10202001501QA
(en)
|
2015-08-20 |
2020-04-29 |
Janssen Vaccines & Prevention Bv |
Therapeutic hpv18 vaccines
|
WO2017060329A1
(en)
|
2015-10-06 |
2017-04-13 |
Janssen Vaccines & Prevention B.V. |
Methods for preventing plastic-induced degradation of biologicals
|
WO2017074517A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Seracare Life Sciences, Inc. |
Adenovirus control virus
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
WO2017079442A1
(en)
|
2015-11-04 |
2017-05-11 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
WO2017174568A1
(en)
|
2016-04-05 |
2017-10-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f proteins
|
MX2018012095A
(es)
|
2016-04-05 |
2019-01-10 |
Janssen Vaccines & Prevention Bv |
Vacuna contra vrs.
|
EP3448881B1
(en)
|
2016-04-26 |
2023-06-07 |
Icahn School of Medicine at Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
EP3452087A1
(en)
|
2016-05-02 |
2019-03-13 |
Janssen Vaccines & Prevention B.V. |
Therapeutic hpv vaccine combinations
|
US20190134190A1
(en)
|
2016-05-04 |
2019-05-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
JP7046835B2
(ja)
|
2016-05-12 |
2022-04-04 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
強力でバランスのとれた双方向性プロモーター
|
DK3464331T3
(da)
|
2016-05-30 |
2021-01-18 |
Janssen Vaccines & Prevention Bv |
Stabiliserede præfusions-rsv f-proteiner
|
BR112018075969A2
(pt)
|
2016-06-20 |
2019-04-02 |
Janssen Vaccines & Prevention B.V. |
promotor bidirecional potente e equilibrado
|
US11091795B2
(en)
|
2016-07-11 |
2021-08-17 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for diagnosing and treating arrhythmias
|
JP7229151B2
(ja)
|
2016-07-14 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Hpvワクチン
|
WO2018064523A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
WO2018069316A2
(en)
|
2016-10-10 |
2018-04-19 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
AU2018205496A1
(en)
|
2017-01-07 |
2019-07-25 |
Selecta Biosciences, Inc. |
Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
|
US11241436B2
(en)
|
2017-01-25 |
2022-02-08 |
Northwestern University |
Autophagy inducers for treatment of CNS conditions
|
US11034978B2
(en)
|
2017-02-09 |
2021-06-15 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
CN110914413A
(zh)
|
2017-02-17 |
2020-03-24 |
隆萨有限公司 |
产生腺相关病毒的哺乳动物细胞
|
WO2018194438A1
(ko)
|
2017-04-21 |
2018-10-25 |
(주)지뉴인텍 |
비복제 아데노 바이러스 생산 세포주 및 이의 제조방법
|
JP2020519663A
(ja)
|
2017-05-17 |
2020-07-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
Rsv感染に対する防御免疫を誘導するための方法及び組成物
|
EP3681533A1
(en)
|
2017-09-15 |
2020-07-22 |
Janssen Vaccines & Prevention B.V. |
Method for the safe induction of immunity against rsv
|
CN111542336A
(zh)
|
2017-10-13 |
2020-08-14 |
西莱克塔生物科技公司 |
用于减弱抗病毒转移载体igm应答的方法和组合物
|
CA3077630A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
MX2020004488A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
SG11202003399TA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
SG11202003200VA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
CA3083183A1
(en)
|
2017-11-22 |
2019-05-31 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cancer
|
WO2019118480A1
(en)
|
2017-12-11 |
2019-06-20 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and uses thereof
|
HRP20220980T1
(hr)
|
2018-01-23 |
2022-11-11 |
Janssen Vaccines & Prevention B.V. |
Cjepiva protiv virusa influence i njihova uporaba
|
KR20200128703A
(ko)
|
2018-03-06 |
2020-11-16 |
프레시전 인코포레이티드 |
B형 간염 백신 및 이의 용도
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
***新抗原及其用途
|
AU2020263900A1
(en)
|
2019-04-25 |
2021-10-14 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
US20200360453A1
(en)
|
2019-04-28 |
2020-11-19 |
Selecta Biosciences, Inc. |
Methods for treatment of subjects with preexisting immunity to viral transfer vectors
|
CN113950333A
(zh)
|
2019-05-15 |
2022-01-18 |
扬森疫苗与预防公司 |
使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
|
US20220273787A1
(en)
|
2019-05-15 |
2022-09-01 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
WO2020229581A1
(en)
|
2019-05-16 |
2020-11-19 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing a safe immune response against polio virus
|
WO2020243261A1
(en)
|
2019-05-28 |
2020-12-03 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
WO2021043869A1
(en)
|
2019-09-05 |
2021-03-11 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
JP2022551107A
(ja)
|
2019-10-03 |
2022-12-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベクターおよびその使用
|
CN114761546A
(zh)
|
2019-10-08 |
2022-07-15 |
波士顿学院董事会 |
含有多个不同非天然氨基酸的蛋白质以及制备和使用此类蛋白质的方法
|
CN114980920A
(zh)
|
2019-11-18 |
2022-08-30 |
詹森生物科技公司 |
基于突变体calr和jak2的疫苗及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
WO2022074464A2
(en)
|
2020-03-05 |
2022-04-14 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
US20210315986A1
(en)
|
2020-04-13 |
2021-10-14 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
CN115698078A
(zh)
|
2020-04-21 |
2023-02-03 |
Jjp佰优罗机克斯有限公司 |
人源化抗人cd89抗体及其用途
|
US20230029453A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
EP4176087A1
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
KR20230038496A
(ko)
|
2020-07-13 |
2023-03-20 |
트랜스진 |
면역 억제의 치료
|
JP2023537818A
(ja)
|
2020-08-11 |
2023-09-06 |
マスキュロスケレタル トランスプラント ファウンデーション |
胎盤由来組成物を用いた心疾患を治療するための方法
|
EP4340855A1
(en)
|
2021-08-13 |
2024-03-27 |
Triovance Holding LLC |
A skin substitute composition and methods of producing and using the same
|
WO2023064367A1
(en)
|
2021-10-12 |
2023-04-20 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
EP4338727A1
(en)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus formulations
|